CARDIFF ONCOLOGY INC. 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors Nominees: Gary W. Pace, Ph.D.

CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Gary W. Pace, Ph.D.”): 21,230,105 for, 0 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,707,076 for, 3,838 withheld.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Dr. James O. Armitage

CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Dr. James O. Armitage”): 20,521,597 for, 0 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,710,914 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Lale White

CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Lale White”): 20,380,890 for, 0 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,710,914 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Mani Mohindru, Ph.D.

CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Mani Mohindru, Ph.D.”): 20,590,042 for, 0 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,710,914 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Mark Erlander, Ph.D.

CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Mark Erlander, Ph.D.”): 20,509,615 for, 0 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,710,914 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Renee P. Tannenbaum, Pharm.D.

CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Renee P. Tannenbaum, Pharm.D.”): 20,560,088 for, 0 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,710,914 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Dr. Rodney Markin

CARDIFF ONCOLOGY INC.’s own tally for this item (“Elect Director: Dr. Rodney Markin”): 20,730,735 for, 0 against, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the seven (7) nominees for director were elected to serve until the 2026 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,706,218 for, 4,696 withheld.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Proposal to approve an amendment to the Company's 2021 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 12,150,000 shares from 8,150,000 shares.

CARDIFF ONCOLOGY INC.’s own tally for this item (“3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 12,150,000 shares”): 16,897,666 for, 4,974,504 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 12,150,000 shares was approved by the stockholders by the votes set forth in the table below:”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,652,242 for, 55,230 against.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: PROPOSAL TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

CARDIFF ONCOLOGY INC.’s own tally for this item (“4. Advisory vote on the compensation of the Company's named executive officers”): 18,881,817 for, 2,576,465 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The advisory vote on the compensation of the Company's named executive officers was approved by the stockholders by the votes set forth in the table below:”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 32 managers: 2,688,907 for, 22,007 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 89 managers: 7,657,165 for, 40,045 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Proposal to ratify BDO USA, P.C. as the Company's independent registered public accountants for fiscal year ending December 31, 2025.

CARDIFF ONCOLOGY INC.’s own tally for this item (“2. Appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2025”): 36,346,950 for, 1,233,336 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2025 was ratified and approved by the stockholders by the votes set forth in the table below:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 2,710,914 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.